samedan logo
 
 
spacer
home > white papers > How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction - Temptime Corporation
WHITE PAPERS
logo_Temptime_C.png

Temptime Corporation

phone +1 973 984 6009
email info@temptimecorp.com
web http://temptimecorp.com/edge-wireless-connected-sensors/
email 116 The American Road, Morris Plains, 07950, New Jersey

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Innovation at CPhI Worldwide: Duma Pocket – the pharmaceutical packaging that doesn’t look like medicine

Düsseldorf/Frankfurt, October 24, 2017. Patients prefer pharmaceutical packaging that does not give away its contents at first glance. With their oval shape, Gerresheimer’s extremely handy Duma Pocket containers look more like boxes of sweeteners, chewing gum or peppermints. The Duma Pocket is available in many different sizes and colors and with various closures. Gerresheimer is expanding its range of this tried-and-tested packaging with the addition of the 40 ml Duma Pocket CR Box and the 100 ml Duma Pocket CR 100 for large filling volumes.
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>


Industry Events

Drug Delivery Partnerships 2018

22-24 January 2018, PGA National Resort & Spa, Palm Beach Gardens, Florida

For 22 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement